Skip to main content
Signal8

Liminatus Pharma, Inc. (LIMN) Form 8-K — Jul 6, 2026

$LIMNForm 8-KItems 1.01, 2.01, 3.02, 5.03, 9.01Filed Jul 6, 2026, 8:00 AM ET0001104659-26-080613Original filing

Liminatus Pharma completed its acquisition of InnocsAI LLC on July 2, 2026, pursuant to an Amended and Restated Merger Agreement. The transaction closed prior to receiving stockholder approval, allowing the immediate acquisition of InnocsAI's CAR-T therapy technology assets and intellectual property. The total consideration for the transaction consists of 1.6 billion shares of Liminatus common stock, valued at $0.20 per share. To comply with Nasdaq listing rules regarding issuance without shareholder approval, 11,188,729 shares of common stock and 158,881.1271 shares of Series A Non-Voting Convertible Preferred Stock were issued at closing.

Key figures

Issuance Price
0.2
Conversion Ratio
10000
Common Stock Issued
11188729
Nasdaq Issuance Cap
19.99%
Merger Consideration Shares
1600000000

Price after filing

1 day: -9.2%7 days: -24.0%30 days: -17.1%

Close on the filing date to close N calendar days later (from $0.14). Historical, not a forecast.

AI analysis

Red flags4 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.

    Liminatus Pharma, Inc. (LIMN) Form 8-K — Jul 6, 2026: AI Analysis | Signal8